

# Thuy Nguyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4292252/publications.pdf>

Version: 2024-02-01

15  
papers

317  
citations

1039880

9  
h-index

996849

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

420  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropeptide B/W receptor 1 peptidomimetic agonists: Structure-activity relationships and plasma stability. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114149.	2.6	3
2	RTICBM-74 Is a Brain-Penetrant Cannabinoid Receptor Subtype 1 Allosteric Modulator that Reduces Alcohol Intake in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 380, 153-161.	1.3	3
3	Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 257-270.	2.9	7
4	Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 41, 116215.	1.4	7
5	Neuropeptide FF and Its Receptors: Therapeutic Applications and Ligand Development. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12387-12402.	2.9	20
6	Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. <i>British Journal of Anaesthesia</i> , 2020, 125, 596-604.	1.5	24
7	Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9806-9823.	2.9	12
8	Diarylureas Containing 5-Membered Heterocycles as CB <sub>1</sub> Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation. <i>ACS Chemical Neuroscience</i> , 2019, 10, 518-527.	1.7	8
9	Overcoming the Psychiatric Side Effects of the Cannabinoid CB <sub>1</sub> Receptor Antagonists: Current Approaches for Therapeutics Development. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1418-1435.	1.0	69
10	Synthesis of Enantiopure PZM21: A Biased Agonist of the Mu $\mu$ Opioid Receptor. <i>European Journal of Organic Chemistry</i> , 2018, 2018, 4006-4012.	1.2	3
11	Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB <sub>1</sub> Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7410-7424.	2.9	21
12	The great divide: Separation between in $\mu$ vitro and in $\mu$ vivo effects of PSNCBAM-based CB <sub>1</sub> receptor allosteric modulators. <i>Neuropharmacology</i> , 2017, 125, 365-375.	2.0	23
13	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB <sub>1</sub> Receptor. <i>Medicinal Research Reviews</i> , 2017, 37, 441-474.	5.0	76
14	Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2290-2308.	1.7	10
15	Structure $\mu$ activity relationships of substituted 1H-indole-2-carboxamides as CB <sub>1</sub> receptor allosteric modulators. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2195-2203.	1.4	31